Evidence map›Paper›PMID 40486613›Full record

ArticleAnnals of medicine and surgery (2012)2025

A case of renal cell carcinoma with tumor thrombus extension into the right atrium.

Adrian Whiting, Nairuti Shah, Jordan Zucker, Manroop Gill, Eliot Sachsenmeier, Paramvir Singh, Kinza Ahmed, Rutul Upadhyay, Michael Bender

Abstract readCase Reports
In one paragraph

Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adrian WhitingDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.ORCID https://orcid.org/0000-0002-6446-3720
Nairuti ShahDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.
Jordan ZuckerDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.
Manroop GillDepartment of Internal Medicine, Maimonides Medical Center, Brooklyn, New York.
Eliot SachsenmeierDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.
Paramvir SinghDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.
Kinza AhmedDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.
Rutul UpadhyayDepartment of Internal Medicine, NYU Langone Hospital - Long Island, Long Island, New York.
Michael BenderDepartment of Pulmonary and Critical Care Medicine, NYU Langone Hospital - Long Island, Long Island, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Over the last half-century, mortality from renal cell carcinoma (RCC) has seen a dramatic reduction, while 5-year survival rates have reached an all-time high (34% to 75%). Case presentation: A 77-year-old female with Stage 4 RCC (cT3c, cN1, cM1) presented with acute onset chest and back pain. Imaging revealed interval enlargement of a left renal mass with propagation of tumor thrombus (TT) throughout the left renal vein, intrahepatic and suprahepatic inferior vena cava (IVC) with extension into the right atrium (RA). The patient successfully underwent a high-risk open left nephrectomy with caval thrombectomy, retroperitoneal lymph node dissection, and atrial thrombectomy. Discussion: Approximately, 1% of RCC cases involve the right atrium, and radical nephrectomy with vena caval thrombectomy remains the most effective treatment for cavoatrial TT, with 5-year survival rates between 30% and 72%. While patients with renal vein involvement have better survival rates than those with IVC involvement, advanced TT cases (Types III and IV) often require extracorporeal circulation. Though the patient understood the prognosis of her RCC, discussing the risks of a complex procedure versus not intervening was challenging. Despite a typical median survival of 12 months for level IV tumor thrombus (TT), she remains stable 28 months post-surgery. Conclusion: Although the 5-year survival rate for renal cell carcinoma (RCC) has increased from 34% to 75%, the disease still adversely affects patients' quality of life. A multidisciplinary approach is essential when managing metastatic RCC, particularly involving the heart. Despite the associated risks, surgical intervention is more effective in prolonging life by preventing sudden cardiac death due to embolic events.

Indexed as

cardiologycase reportnephrologyRCCtumor thrombus

Identifiers

PMID40486613
PMCPMC12140791

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.